MBX Biosciences, Inc.

MBX

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$16.00 10,200,000 Positive High 17.92%

Offering Team

Deal Managers

  • J P Morgan Chase
  • Jefferies
  • Guggenheim

Lawyers

  • Goodwin Procter LLP

Auditors

  • Ernst & Young LLP

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEP™, platform to overcome the key limitations of unmodified and modified peptide therapies More

Deal Tracker

Investors

Filing

23 Aug, 2024

Offer

13 Sep, 2024

Look Ahead

Lock Up Expiry

13 Mar, 2025

Earning

Nov 1, 2018

IPO Terms

Offer Price $16.00
Offer Size 10M

Market Sentiments

Stock Price